中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1244 records (took 0.047 seconds)

    TUMORS EXPRESSING IgG1 Fc INDUCE ROBUST CD8 T CELL RESPONSES
    212.
    发明申请
    TUMORS EXPRESSING IgG1 Fc INDUCE ROBUST CD8 T CELL RESPONSES 审中-公开
    肿瘤表达IgG1 Fc诱导稳定的CD8 T细胞应答

    公开(公告)号：US20170007685A1

    公开(公告)日：2017-01-12

    申请号：US15034113

    申请日：2014-11-05

    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  YALE UNIVERSITY ,  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY

    Inventor： Chandrashekhar PASARE ,  Scott N. FURLAN ,  Noah W. PALM ,  Arun UNNI

    IPC: A61K39/00 ,  C12N5/09

    CPC classification number: A61K39/0011 ,  A61K48/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/572 ,  C12N5/0693 ,  C12N2510/00

    Abstract: A lymphoma cell line was engineered to express surface IgG1 Fc. These tumor cells were taken up rapidly by DCs, leading to enhanced cross-presentation of tumor-derived antigen to CD8 T cells. IgG1-Fc tumors failed to grow in vivo and prophylactic vaccination in an animal model resulted in rejection of unmanipulated tumor cells. Furthermore, IgG1-Fc tumor cells were able to slow the growth of an unmanipulated primary tumor when used as a therapeutic tumor vaccine. This demonstrates that engagement of Fc receptors by tumors expressing the Fc region of IgG1 can induce efficient and protective anti-tumor CD8+ T cell responses without prior knowledge of tumor-specific antigen.

    Abstract translation: 将淋巴瘤细胞系工程化以表达表面IgG1 Fc。 这些肿瘤细胞被DC迅速吸收，导致肿瘤衍生的抗原与CD8T细胞的交叉表达增强。 IgG1-Fc肿瘤体内无法生长，动物模型中的预防性接种导致未操作的肿瘤细胞的排斥。 此外，当用作治疗性肿瘤疫苗时，IgG1-Fc肿瘤细胞能够减缓未操作的原发性肿瘤的生长。 这表明，通过表达IgG1的Fc区的肿瘤的Fc受体的参与可以在没有肿瘤特异性抗原的先验知识的情况下诱导有效和保护性的抗肿瘤CD8 + T细胞应答。

    INHIBITORS OF MITOCHONDRIAL PYRUVATE DEHYDROGENASE KINASE ISOFORMS 1-4 AND USES THEREOF
    214.
    发明申请
    INHIBITORS OF MITOCHONDRIAL PYRUVATE DEHYDROGENASE KINASE ISOFORMS 1-4 AND USES THEREOF 审中-公开
    MITOCHONDRY PYRUVATE DEHYDROGENASE KINASE ISOFORS 1-4的抑制剂及其用途

    公开(公告)号：US20170001958A1

    公开(公告)日：2017-01-05

    申请号：US15103619

    申请日：2014-12-12

    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

    Inventor： David T. CHUANG ,  Shih-Chia TSO ,  Xiangbing QI ,  Wen-Jun GUI ,  Cheng-Yang WU ,  Jacinta L. CHUANG ,  Uttam K. TAMBAR ,  R. Max WYNN

    IPC: C07D209/44 ,  C07D401/12

    CPC classification number: C07D209/44 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D487/08

    Abstract: The present disclosure relates to the identification of PDK inhibitors and their use in the treatment of diseases such as diabetes, cardiovascular disease and cancer. The invention relates to the development of robust PDK inhibitors that can be used to improve glucose metabolism and correct metabolic dysfunction in vivo. Based on the unique structural features present in the ATP-binding pocket of PDK2, a single functional-group change was made in a known Hsp90 inhibitor that binds to the corresponding pocket of the latter protein from the GHKL family. This approach efficiently converted the Hsp90 inhibitor to a highly specific inhibitor for all PDK isoforms. These final PDK inhibitors of this series robustly augments PDC activity with reduced phosphorylation in tissues.

    Abstract translation: 本公开涉及PDK抑制剂的鉴定及其在治疗糖尿病，心血管疾病和癌症等疾病中的用途。 本发明涉及可用于改善体内葡萄糖代谢和纠正代谢功能障碍的强力PDK抑制剂的开发。 基于PDK2的ATP结合口袋中存在的独特的结构特征，在已知的Hsp90抑制剂中进行单个官能团变化，其结合来自GHKL家族的后一种蛋白质的相应口袋。 该方法有效地将Hsp90抑制剂转化为所有PDK异构体的高度特异性抑制剂。 这些系列的这些最终的PDK抑制剂强力地增加PDC活性，减少组织中的磷酸化。

    Exclusive-OR gate using magneto-electric tunnel junctions
    215.
    发明授权
    Exclusive-OR gate using magneto-electric tunnel junctions 有权
    使用磁电隧道结的异或门

    公开(公告)号：US09503085B1

    公开(公告)日：2016-11-22

    申请号：US14871199

    申请日：2015-09-30

    Applicant: The Research Foundation for the State University of New York ,  The Board of Regents of The University of Texas System

    Inventor： Jonathan Paul Bird ,  Andrew Marshall

    IPC: H03K19/21 ,  H03K19/00 ,  H03K19/16 ,  H01L43/08 ,  G11C11/16

    CPC classification number: H03K19/0008 ,  G11C11/161 ,  G11C11/1673 ,  G11C11/1675 ,  H01L43/08 ,  H03K19/16 ,  H03K19/21

    Abstract: A magneto-electric (ME) magnetic tunnel junction (MTJ) Exclusive-OR (XOR) gate is provided. The ME MTJ XOR gate includes an insulator separating a top ferromagnetic (FM) layer and a bottom FM layer, a top ME layer on the top FM layer, and a bottom ME layer on the bottom FM layer. The ME MTJ XOR gate also includes a top electrode coupled to the top ME layer and a bottom electrode coupled to the bottom ME layer where a voltage between the top electrode and the top FM layer is a first input, a voltage between the bottom electrode and the bottom FM layer is a second input, and a resistance between the top FM layer and the bottom FM layer is indicative of the XOR of the first input and the second input. The ME MTJ XOR has reduced energy consumption, smaller area, faster switching times, and is non-volatile.

    Abstract translation: 提供磁电（ME）磁性隧道结（MTJ）异或（XOR）门。 ME MTJ XOR门包括分离顶部铁磁（FM）层和底部FM层的绝缘体，顶部FM层上的顶部ME层和底部FM层上的底部ME层。 ME MTJ XOR门还包括耦合到顶部ME层的顶部电极和耦合到底部ME层的底部电极，其中顶部电极和顶部FM层之间的电压是第一输入，底部电极和 底部FM层是第二输入，并且顶部FM层和底部FM层之间的电阻指示第一输入和第二输入的异或。 ME MTJ XOR降低了能耗，面积更小，切换时间更快，是非易失性的。

    EUROPIUM-DOPED PHOSPHOR MATERIALS
    219.
    发明申请
    EUROPIUM-DOPED PHOSPHOR MATERIALS 审中-公开
    欧式磷光体材料

    公开(公告)号：US20160264861A1

    公开(公告)日：2016-09-15

    申请号：US15034124

    申请日：2014-11-06

    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

    Inventor： Wei Chen ,  Lun Ma

    IPC: C09K11/77

    CPC classification number: C09K11/773

    Abstract: This invention relates to new phosphor materials exhibiting luminescence and methods for their production. More particularly, the invention relates to new europium-doped zinc sulfide-manganese (ZnS:Mn,Eu) phosphors and use thereof for radiation detection.

    Abstract translation: 本发明涉及具有发光的新型磷光体材料及其生产方法。 更具体地说，本发明涉及新的铕掺杂的硫化锌 - 锰（ZnS：Mn，Eu）荧光体及其用于辐射检测的用途。

Patent Agency Ranking